HALO logo
halo search icon
Soleno Therapeutics Inc
Soleno Therapeutics Inc
SLNO · NAS

Soleno Therapeutics Inc

US$53.01

0.00 (0.00%)
19/05/2026 12:00:00 AM
All-CompaniesAll-ConsensusHALO AllNear ResistanceRecent Earnings downgrade
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Soleno Therapeutics Inc Overview

SLNO Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Strong

Growth

Earnings

Very Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About SLNO

icon

Website

Soleno Therapeutics Inc

icon

Telephone

1.650.213.8444

icon

Address

Suite 400, 100 Marine Parkway, Redwood City, CA 94065

Description

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

SLNO Price Chart

Key Stats

Market Cap

US$2.76B

PE

118.40

EV/EBITDA

127.9

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 29.43 - 90.32

Trade Value (12mth)

US$28,510,853.00

1 week

0%

1 month

0.49%

YTD

12.38%

1 year

-28.26%

All time high

742.50

Key Fundamentals

EPS 3 yr Growth

-114.10%

EBITDA Margin

8.90%

Operating Cashflow

$47m

Free Cash Flow Return

11.70%

ROIC

5.10%

Interest Coverage

3.10

Quick Ratio

5.60

Other Data

Shares Outstanding (Fully Diluted)

53m

HALO Sector

Healthcare

Next Company Report Date

03-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

SLNO Announcements

Latest Announcements

DateAnnouncements
18 May 26
18 May 26
18 May 26
18 May 26
08 May 26

SLNO Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-2.36-4.380.4locklocklock
EPS (Fully Diluted)
$locklocklocklock-2.36-4.380.39locklocklock
Growth
%locklocklocklock17.5-85.2109.2locklocklock
PE
XlocklocklocklockN/AN/A118.4locklocklock
EV/EBITDA
XlocklocklocklockN/AN/A127.9locklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Soleno Therapeutics Inc (SLNO:NAS)?
Halo FAQ
The current share price of Soleno Therapeutics Inc (SLNO:NAS) is USD$53.01.
What is the 52-week high share price for Soleno Therapeutics Inc (SLNO:NAS)?
Halo FAQ
The 52-week high share price for Soleno Therapeutics Inc (SLNO:NAS) is USD$90.32.
What is the 52-week low share price for Soleno Therapeutics Inc (SLNO:NAS)?
Halo FAQ
The 52-week low share price for Soleno Therapeutics Inc (SLNO:NAS) is USD$29.43.
What is the dividend yield for Soleno Therapeutics Inc (SLNO:NAS)?
Halo FAQ
Soleno Therapeutics Inc (SLNO:NAS) does not pay a dividend.
What was Soleno Therapeutics Inc (SLNO:NAS) last dividend payment?
Halo FAQ
Soleno Therapeutics Inc (SLNO:NAS) does not pay a dividend.
What is the franking level for Soleno Therapeutics Inc (SLNO:NAS)?
Halo FAQ
Soleno Therapeutics Inc (SLNO:NAS) has a franking level of 0.00%.
In which sector is Soleno Therapeutics Inc (SLNO:NAS) classified?
Halo FAQ
Soleno Therapeutics Inc (SLNO:NAS) is classified in the Healthcare.
What is the price-to-earnings (P/E) ratio for Soleno Therapeutics Inc (SLNO:NAS)?
Halo FAQ
The current P/E ratio for Soleno Therapeutics Inc (SLNO:NAS) is 118.40.

See beyond the curve.

One solution for research, investing and portfolio management.